Catalyst Brief

← Calendar

Readoutin 164d

Novartis Pharmaceuticals — Remibrutinib Dose A

Phase 3 primary completion: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1).

Date
May 2027
Type
Readout
Indication
Hidradenitis Suppurativa

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novartis Pharmaceuticals

  1. May2027
  2. Apr2027
  3. Mar2027
  4. Feb2027
  5. Feb2027
    Readoutin 75d
    Novartis Pharmaceuticals — everolimus
    Phase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.